Thomas Sinegre Selected Research

Thomas Sinegre Research Topics

6	Fibrosis (Cirrhosis) 02/2024 - 03/2016
5	Thrombophilia 02/2024 - 04/2017
2	Hemorrhage 01/2023 - 06/2015
2	Venous Thromboembolism 01/2022 - 06/2019
1	Thrombosis (Thrombus) 02/2023
1	Hyperlipidemias (Hyperlipidemia) 01/2022
1	Hemolysis 01/2022
1	Jaundice (Icterus) 01/2022
1	Protein C Deficiency 09/2020
1	Hemophilia B (Haemophilia B) 05/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2019
1	Acquired Protein S Deficiency 04/2017
1	Acquired Protein C Deficiency 04/2017
1	Cerebral Hemorrhage 06/2015
1	Subdural Hematoma (Subdural Hemorrhage) 06/2015

7	Thrombin FDA Link 02/2024 - 06/2015
4	ThrombomodulinIBA 02/2024 - 04/2017
3	Prothrombin (Factor II)IBA 02/2024 - 06/2015
3	AnticoagulantsIBA 01/2023 - 11/2019
2	AntithrombinsIBA 02/2024 - 09/2020
2	Protein CIBA 02/2024 - 04/2017
1	Heparin (Liquaemin)FDA LinkGeneric 02/2023
1	Factor Xa (Coagulation Factor Xa)IBA 02/2023
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2023
1	Cytidine Triphosphate (CTP)IBA 01/2023
1	Vitamin K FDA Link 01/2023
1	Thromboplastin (Tissue Factor)IBA 01/2023
1	fibrin fragment D (D-dimer)IBA 01/2022
1	phospholipid emulsion soybean oil (Intralipid)IBA 01/2022
1	AntibodiesIBA 01/2022
1	BilirubinIBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	Rheumatoid FactorIBA 01/2022
1	factor IX Fc fusion proteinIBA 05/2020
1	Catechin (Z 7300)IBA 11/2019
1	A-factor (Streptomyces)IBA 06/2019
1	edoxabanIBA 06/2019
1	Hemostatics (Antihemorrhagics)IBA 03/2016
1	RivaroxabanIBA 06/2015

1	Therapeutics 01/2023
1	Anticoagulation Reversal 06/2015